Novartis radioligand therapy Pluvicto gets USFDA nod for expanded indication Ruchika Sharma29 March 2025 1:15 PM ISTBasel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for...
Despite Pluvicto, MorphoSys Setbacks, Novartis Raises 2028 Sales Growth Outlook to 6% Farhat Nasim24 Nov 2024 10:30 AM ISTFrankfrut: Novartis raised its medium-term sales guidance on Thursday to 6 percent annual growth through 2028, driven by momentum of launched...
Novartis expands production of Pluvicto with addition of its largest, most advanced radioligand therapy manufacturing facility in Indianapolis Ruchika Sharma7 Jan 2024 2:30 PM ISTBasel: Novartis has announced that it has received approval from the US Food and Drug Administration (FDA) for commercial manufacturing of...
Novartis raises sales growth target to 5 percent a year through 2027 Ruchika Sharma28 Nov 2023 3:30 PM ISTFrankfurt: Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after the spin off of...
Novartis Millburn facility gets USFDA nod for US commercial production of Pluvicto Ruchika Sharma24 April 2023 2:15 PM ISTUnited States: Novartis has received US Food and Drug Administration (FDA) approval to begin supplying Pluvicto for US commercial use from the...
Novartis gets European Commission nod for Pluvicto to treat progressive PSMA-positive metastatic castration-resistant prostate cancer Ruchika Sharma17 Jan 2023 3:30 PM ISTPluvicto is an intravenous radioligand therapy combining a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in...
Novartis prostate cancer therapy Pluvicto bags European Commission nod Ruchika Sharma14 Dec 2022 4:15 PM IST"The approval of Pluvicto by the European Commission marks a major milestone for patients with advanced prostate cancer who have few alternative...
Novartis gets positive EMA panel opinion for prostate cancer drug Pluvicto Ruchika Sharma17 Oct 2022 11:32 AM ISTPluvicto is a radioligand therapy combining a targeting compound (ligand, in this case directed to PSMA) with a therapeutic radioisotope
Novartis to prioritise US market, unfazed by drug pricing pushback Ruchika Sharma25 Sept 2022 2:51 PM ISTNovartis aspire to "organically build its U.S. business to become a top-five player in the U.S. by 2027," it said in a statement.
Novartis suspends two cancer therapies over quality concerns Ruchika Sharma6 May 2022 12:19 PM ISTZurich: Novartis said on Thursday it had temporarily suspended the production of its Lutathera and Pluvicto cancer therapies at facilities in Italy...
Novartis gets USFDA nod for Pluvicto to treat prostate cancer Ruchika Sharma27 March 2022 10:00 AM ISTBasel: Novartis has recently announced that the US Food and Drug Administration (USFDA) has approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan)...
